Triple G 20mg mg vial GLP3

Triple G GLP3 (Retatrutide 20 mg) – Product Information

Triple G GLP3 (Retatrutide 20 mg), also known as GLP3 rheta, Triple G or LY3437943, is a synthetic research peptide belonging to the class of triple agonists of the GLP-1, GIP, and glucagon receptors. This compound was developed as a multireceptor molecule, enabling the simultaneous analysis of three key signaling pathways involved in the regulation of metabolism, glucose homeostasis, and energy balance.

A distinctive feature Retatrutide 20 mg is its activity at the GLP-1R, GIPR, and GCGR receptors. GLP-1 receptor activation is studied in the context of incretin signaling, the glucose-dependent insulinotropic response, regulation of food intake, and mechanisms related to satiety. The GIP receptor remains an important target of research on glucose homeostasis and metabolic response, while the glucagon component is studied in terms of energy metabolism, the mobilization of metabolic substrates, and lipid metabolism.

See also Triple G 20 MG PEN

The combination of three receptor profiles in a single molecule sets it apart GLP3 rheta from classic GLP-1 agonists and dual-action compounds that act simultaneously on GLP-1 and GIP receptors. For this reason, retatrutide is an interesting research subject in projects related to modern metabolic pharmacology, incretin receptor physiology, and the relationships between GLP-1, GIP, and glucagon signaling.

The declared content of the product is 20 mg retatrutide, which allows the material to be used in qualitative analyses, comparative studies, and reference procedures conducted under laboratory conditions. The product is intended solely for scientific research, laboratory analyses, and reference applications.

Where to Buy Retatrutide 20 mg and Online Availability

Retatrutide 20 mg It is not currently available as an approved medicinal product in pharmacies. The substance remains the subject of advanced clinical trials and is still being studied as part of development programs for multireceptor agonists.

In online retail, you can find products described as GLP3 rheta, Triple G peptide, Retatrutide 20 mg or LY3437943 research peptide. Products of this type are offered as "research use only" materials, intended for laboratory analysis and reference purposes.

When selecting a research product, information regarding the declared content, purity of the material, product form, quality documentation, and storage conditions is of significant importance. Retatrutide, available online as a research reagent, is not a medicinal product and should be used exclusively under controlled laboratory conditions.

Also check out GLP-1 (Orforglipron) capsules 5mg/60caps.

Research on Retatrutide 20 mg

Retatrutide has attracted significant interest from the scientific community due to its simultaneous activity against GLP-1, GIP, and glucagon receptors. Published clinical studies have examined its effects on body weight, glycemic control, body composition, and other parameters related to metabolism and energy balance.

A Phase 2 study published in the *New England Journal of Medicine* evaluated retatrutide in obese or overweight adults. During the 48-week follow-up period, various dose levels and a gradual escalation of the study drug were analyzed. The results showed a clear correlation between the level of exposure and the observed changes in body weight. In the groups receiving the highest doses, the average weight loss reached approximately 24%, highlighting the scientific potential of triple receptor activation.

Further analyses indicated that the observed changes in body weight occurred gradually over the course of the study and did not reach a clear plateau by the end of the 48-week observation period. Publications on body composition also analyzed the proportions of changes in body fat and lean body mass, which allowed for a broader assessment of the compound’s effect on metabolic processes.

Retatrutide was also studied in participants with type 2 diabetes. These studies evaluated, among other things, changes in blood glucose levels, glycated hemoglobin levels, body weight, and selected cardiometabolic parameters. The results indicated activation of mechanisms characteristic of GLP-1 and GIP receptors, supplemented by a glucagon component associated with the regulation of energy expenditure and substrate metabolism.

In the scientific literature Triple G GLP3 It is currently described as one of the most advanced triple receptor agonists. A growing body of research makes retatrutide a valuable research tool in studies involving incretin signaling, glucose metabolism, energy balance regulation, lipid metabolism, and comparisons of single, dual, and triple agonists.

Scientific sources:

https://pubmed.ncbi.nlm.nih.gov/37366315/

https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

https://pubmed.ncbi.nlm.nih.gov/37385280/

https://pubmed.ncbi.nlm.nih.gov/38858523/

https://www.nejm.org/doi/abs/10.1056/NEJMe2307282